Abstract:Introduction: The recreational use of psilocybin or psilocin-containing products, a chemical found naturally in certain mushroom species, is on the rise across the United States. Several cases of serious clinical effects related to mushroom-containing products have recently been reported to the Food and Drug Administration (FDA). The emergence of these new products and their health consequences are not yet well understood. This case series aims to characterize exposures to mushroom-containing chocolate products, including patient characteristics, clinical effects, treatment(s), and clinical outcome severity, reported to a poison center network. Material and methods: This was a retrospective case series conducted in patients exposed to mushroom-containing chocolate products across three poison centers between January 2023 to August 2024. Patients were identified via a database search of ToxSentry®. Patients were included if they were exposed to a mushroom-containing chocolate product. Patients were excluded if they ingested an unrelated product or if there was insufficient information documented within ToxSentry®. The primary endpoint was to describe clinical outcome severity after exposure to mushroom-containing chocolate products. Results: A query of ToxSentry® identified 164 cases; 36 cases met study criteria. The median age of patients in this case series was 17 years old. For most patients (23, 64 %), the reason for the exposure was intentional, with 20 reporting intentional abuse or misuse of the product. Common clinical effects reported included mental status changes (26, 76 %), paranoia/hallucinations (10, 28 %), dysrhythmias (7, 19 %) and gastrointestinal discomfort (6, 17 %). There was one report of seizure. Most clinical effects lasted between 3 and 24 h after ingestion (29, 81 %). Intravenous fluids (18, 50 %) and benzodiazepines (7, 19 %) were the most common treatments given. No fatalities were reported. Discussion: While most patients in this series experienced minor clinical effects, some developed serious effects after ingestion of a mushroom-containing chocolate product. Findings from this study further characterize the limited patient demographics, clinical effects, and outcomes published thus far. Further characterization in a larger cohort of patients could expand on our initial findings and is needed to better identify factors that may influence clinical outcomes.

A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient

Psychiatric risks for worsened mental health after psychedelic use

Psychedelic use and psychiatric risks

The cyclical revival of psychedelics in psychiatric treatment

Impact of psilocybin on cognitive function: A systematic review

The therapeutic potential of psilocybin: a systematic review

Evaluating the potential for psilocybin as a treatment for post-traumatic stress disorder

[Up-to-Date on clinical and preclinical studies of psilocybin therapy]

Acute Adverse Effects of Therapeutic Doses of Psilocybin

Psychedelic risks and benefits: A cross-sectional survey study

Psilocybin Exposures Reported to US Poison Centers: National Trends Over a Decade

The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges

New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report

The role of psilocybin in depressive disorders

Psychedelic mushroom-containing chocolate exposures: Case series

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults

Palliative care patients' attitudes and openness towards psilocybin-assisted psychotherapy for existential distress

Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians

Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats

Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy

Psilocybin-assisted psychotherapy for existential distress: practical considerations for therapeutic application-a review